By Fineline Cube Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) announced that its investigational product GR2302 (subcutaneous injection formulation) has received Investigational New Drug (IND) approval in China for clinical trials targeting chronic hepatitis B (CHB), advancing a first‑in‑class immunotherapy approach against one of Asia’s most prevalent viral diseases.
IND Approval Summary
| Item | Detail |
|---|---|
| Company | Genrix Bio (SHA: 688443) |
| Product | GR2302 (subcutaneous injection formulation) |
| Drug Class | Bispecific antibody (TCR‑mimic × anti‑CD3) |
| Indication | Chronic hepatitis B (CHB) |
| Regulatory Status | IND approved in China for clinical trials |
| Announcement Date | 19 Aug 2026 |
Drug Profile – GR2302
- Platform: In‑house developed bispecific antibody combining a TCR‑mimic (TCRm) antibody with an anti‑CD3 antibody
- Mechanism – TCRm Arm: Functionally similar to a T‑cell receptor (TCR), the TCRm recognizes peptide‑MHC complexes assembled from specific intracellular antigen peptides and MHC molecules presented on the cell surface; the TCRm component in GR2302 specifically binds with high affinity to the peptide‑MHC complex of the HBV S protein
- Mechanism – T‑Cell Engagement: GR2302 recruits T cells to kill HBV‑infected hepatocytes of the HLA‑A02 subtype
- Therapeutic Potential: Holds potential for treating HBV‑induced hepatitis B and liver cancer, extending the asset’s relevance beyond CHB into hepatocellular carcinoma
Market Impact & Outlook
- Large Unmet Need: China carries one of the world’s highest burdens of chronic hepatitis B, with tens of millions of patients and limited options capable of achieving functional cure — making novel mechanisms like TCRm‑based T‑cell engagers strategically valuable.
- Differentiated Modality: By targeting an intracellular HBV antigen presented as a peptide‑MHC complex, GR2302 can reach HBV‑infected cells that conventional antibodies cannot, a potential advantage over surface‑antigen‑directed approaches.
- Oncology Bridge: The stated potential in HBV‑induced liver cancer positions GR2302 within both infectious disease and oncology franchises, broadening the commercial pathway for Genrix Bio.
- Watch Items: First‑in‑human dose‑escalation design and safety readouts, HLA‑A02‑restricted patient selection strategy, and potential expansion studies in hepatocellular carcinoma.
Forward-Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory outcomes, and commercial expectations for GR2302. Actual results may differ due to risks including early‑stage clinical uncertainty, regulatory decisions, and competitive dynamics in chronic hepatitis B therapies.-Fineline Info & Tech